Last reviewed · How we verify

sulfadoxine-pyrimethamine and chlorproguanil-dapsone

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

sulfadoxine-pyrimethamine and chlorproguanil-dapsone is a Antifolate antimalarial combination Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Malaria treatment and prevention, Plasmodium falciparum malaria in areas with drug resistance.

This combination of two antimalarial drugs works by inhibiting folate synthesis in Plasmodium parasites, preventing DNA replication and parasite growth.

This combination of two antimalarial drugs works by inhibiting folate synthesis in Plasmodium parasites, preventing DNA replication and parasite growth. Used for Malaria treatment and prevention, Plasmodium falciparum malaria in areas with drug resistance.

At a glance

Generic namesulfadoxine-pyrimethamine and chlorproguanil-dapsone
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntifolate antimalarial combination
TargetDihydrofolate reductase; dihydropteroate synthase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Sulfadoxine-pyrimethamine (SP) and chlorproguanil-dapsone (CD) are both antifolate combinations that target sequential steps in the parasite's folate metabolism pathway. Sulfadoxine inhibits dihydropteroate synthase while pyrimethamine inhibits dihydrofolate reductase; similarly, chlorproguanil inhibits dihydrofolate reductase and dapsone inhibits dihydropteroate synthase. This dual mechanism reduces the likelihood of resistance development compared to monotherapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sulfadoxine-pyrimethamine and chlorproguanil-dapsone

What is sulfadoxine-pyrimethamine and chlorproguanil-dapsone?

sulfadoxine-pyrimethamine and chlorproguanil-dapsone is a Antifolate antimalarial combination drug developed by London School of Hygiene and Tropical Medicine, indicated for Malaria treatment and prevention, Plasmodium falciparum malaria in areas with drug resistance.

How does sulfadoxine-pyrimethamine and chlorproguanil-dapsone work?

This combination of two antimalarial drugs works by inhibiting folate synthesis in Plasmodium parasites, preventing DNA replication and parasite growth.

What is sulfadoxine-pyrimethamine and chlorproguanil-dapsone used for?

sulfadoxine-pyrimethamine and chlorproguanil-dapsone is indicated for Malaria treatment and prevention, Plasmodium falciparum malaria in areas with drug resistance.

Who makes sulfadoxine-pyrimethamine and chlorproguanil-dapsone?

sulfadoxine-pyrimethamine and chlorproguanil-dapsone is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

What drug class is sulfadoxine-pyrimethamine and chlorproguanil-dapsone in?

sulfadoxine-pyrimethamine and chlorproguanil-dapsone belongs to the Antifolate antimalarial combination class. See all Antifolate antimalarial combination drugs at /class/antifolate-antimalarial-combination.

What development phase is sulfadoxine-pyrimethamine and chlorproguanil-dapsone in?

sulfadoxine-pyrimethamine and chlorproguanil-dapsone is in Phase 3.

What are the side effects of sulfadoxine-pyrimethamine and chlorproguanil-dapsone?

Common side effects of sulfadoxine-pyrimethamine and chlorproguanil-dapsone include Gastrointestinal disturbances (nausea, vomiting, diarrhea), Rash, Hemolytic anemia (particularly in G6PD-deficient individuals), Headache.

What does sulfadoxine-pyrimethamine and chlorproguanil-dapsone target?

sulfadoxine-pyrimethamine and chlorproguanil-dapsone targets Dihydrofolate reductase; dihydropteroate synthase and is a Antifolate antimalarial combination.

Related